Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Total Valuation
Zevra Therapeutics has a market cap or net worth of $473.53M. The enterprise value is $498.02M.
Market Cap$473.53M
Enterprise Value$498.02M
Share Statistics
Zevra Therapeutics has 54,679,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,679,640
Owned by Insiders0.64%
Owned by Institutions33.94%
Financial Efficiency
Zevra Therapeutics’s return on equity (ROE) is -2.66 and return on invested capital (ROIC) is -70.28%.
Return on Equity (ROE)-2.66
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-70.28%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee400.20K
Profits Per Employee-1.79M
Employee Count59
Asset Turnover0.13
Inventory Turnover3.76
Valuation Ratios
The current PE Ratio of Zevra Therapeutics is -3.66. Zevra Therapeutics’s PEG ratio is -0.35.
PE Ratio-3.66
PS Ratio0.00
PB Ratio11.42
Price to Fair Value9.72
Price to FCF-7.66
Price to Operating Cash Flow-7.59
PEG Ratio-0.35
Income Statement
In the last 12 months, Zevra Therapeutics had revenue of 23.61M and earned -105.51M in profits. Earnings per share was -2.28.
Revenue23.61M
Gross Profit16.20M
Operating Income-87.00M
Pretax Income-90.14M
Net Income-105.51M
EBITDA-76.40M
Earnings Per Share (EPS)-2.28
Cash Flow
In the last 12 months, operating cash flow was -61.72M and capital expenditures -99.00K, giving a free cash flow of -61.82M billion.
Operating Cash Flow-61.72M
Free Cash Flow-61.82M
Free Cash Flow per Share-1.13
Dividends & Yields
Zevra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.91
52-Week Price Change88.72%
50-Day Moving Average7.73
200-Day Moving Average8.00
Relative Strength Index (RSI)64.41
Average Volume (3m)533.56K
Important Dates
Zevra Therapeutics upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date―
Financial Position
Zevra Therapeutics as a current ratio of 2.53, with Debt / Equity ratio of 150.74%
Current Ratio2.53
Quick Ratio2.47
Debt to Market Cap0.16
Net Debt to EBITDA-0.35
Interest Coverage Ratio-11.84
Taxes
In the past 12 months, Zevra Therapeutics has paid 15.37M in taxes.
Income Tax15.37M
Effective Tax Rate-0.17
Enterprise Valuation
Zevra Therapeutics EV to EBITDA ratio is -5.40, with an EV/FCF ratio of -5.92.
EV to Sales17.46
EV to EBITDA-5.40
EV to Free Cash Flow-5.92
EV to Operating Cash Flow-5.92
Balance Sheet
Zevra Therapeutics has $37.34M in cash and marketable securities with $61.84M in debt, giving a net cash position of $24.50M billion.
Cash & Marketable Securities$37.34M
Total Debt$61.84M
Net Cash$24.50M
Net Cash Per Share$0.45
Tangible Book Value Per Share-$0.74
Margins
Gross margin is 78.84%, with operating margin of -368.47%, and net profit margin of -446.85%.
Gross Margin78.84%
Operating Margin-368.47%
Pretax Margin-381.76%
Net Profit Margin-446.85%
EBITDA Margin-323.56%
EBIT Margin-350.62%
Analyst Forecast
The average price target for Zevra Therapeutics is $22.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.43
Price Target Upside152.87% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast44.92%
EPS Growth Forecast-40.06%